Cantor Fitzgerald Predicts Atyr PHARMA FY2025 Earnings

Atyr PHARMA INC (NASDAQ:ATYR) – Stock analysts at Cantor Fitzgerald issued their FY2025 earnings per share estimates for shares of Atyr PHARMA in a report issued on Tuesday, January 21st. Cantor Fitzgerald analyst P. Agrawal anticipates that the company will post earnings per share of ($0.87) for the year. Cantor Fitzgerald currently has a “Overweight” rating on the stock. The consensus estimate for Atyr PHARMA’s current full-year earnings is ($0.91) per share.

ATYR has been the subject of several other research reports. Wells Fargo & Company started coverage on Atyr PHARMA in a report on Friday, October 4th. They set an “overweight” rating and a $17.00 price objective for the company. HC Wainwright restated a “buy” rating and issued a $35.00 target price on shares of Atyr PHARMA in a research note on Tuesday, December 10th. Five analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus price target of $19.25.

Atyr PHARMA Stock Performance

Shares of ATYR opened at $3.50 on Wednesday. Atyr PHARMA has a fifty-two week low of $1.42 and a fifty-two week high of $4.22. The stock has a 50 day simple moving average of $3.40. The stock has a market cap of $293.80 million, a PE ratio of -3.72 and a beta of 1.08. The company has a debt-to-equity ratio of 0.02, a current ratio of 5.41 and a quick ratio of 5.41.

Atyr PHARMA (NASDAQ:ATYR) last posted its quarterly earnings results on Thursday, November 7th. The company reported ($0.23) EPS for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.01).

Institutional Trading of Atyr PHARMA

A hedge fund recently raised its stake in Atyr PHARMA stock. JPMorgan Chase & Co. boosted its stake in shares of Atyr PHARMA INC (NASDAQ:ATYR) by 52.0% during the 3rd quarter, according to its most recent filing with the SEC. The firm owned 31,440 shares of the company’s stock after purchasing an additional 10,754 shares during the period. JPMorgan Chase & Co.’s holdings in Atyr PHARMA were worth $55,000 at the end of the most recent quarter. Institutional investors and hedge funds own 61.72% of the company’s stock.

About Atyr PHARMA

aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.